Insider Selling: Gyre Therapeutics, Inc. (NASDAQ:GYRE) President Sells 2,000 Shares of Stock

Gyre Therapeutics, Inc. (NASDAQ:GYRE) President Songjiang Ma sold 2,000 shares of the business’s stock in a transaction on Friday, January 17th. The shares were sold at an average price of $10.72, for a total transaction of $21,440.00. Following the sale, the president now directly owns 2,907,138 shares of the company’s stock, valued at approximately $31,164,519.36. The trade was a 0.07 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Songjiang Ma also recently made the following trade(s):

• On Wednesday, January 15th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.85, for a total value of $21,700.00.
• On Monday, January 13th, Songjiang Ma sold 56 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.10, for a total value of $565.60.
• On Friday, January 10th, Songjiang Ma sold 1,057 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.02, for a total transaction of $10,591.14.
• On Monday, January 6th, Songjiang Ma sold 941 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.16, for a total value of $9,560.56.
• On Thursday, January 2nd, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $12.40, for a total value of $24,800.00.
• On Monday, December 30th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $12.50, for a total transaction of $25,000.00.
• On Thursday, December 26th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $12.70, for a total value of $25,400.00.
• On Monday, December 23rd, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $12.27, for a total transaction of $24,540.00.
• On Thursday, December 19th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.82, for a total value of $21,640.00.
• On Tuesday, December 17th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $11.05, for a total value of $22,100.00.

Gyre Therapeutics Stock Up 0.1 %

Shares of GYRE traded up $0.01 during trading hours on Tuesday, reaching $10.96. 73,309 shares of the company traded hands, compared to its average volume of 128,639. The stock’s fifty day moving average price is $11.45 and its 200 day moving average price is $12.63. Gyre Therapeutics, Inc. has a 12-month low of $8.26 and a 12-month high of $26.37.

Hedge Funds Weigh In On Gyre Therapeutics

Institutional investors have recently modified their holdings of the stock. FMR LLC bought a new stake in shares of Gyre Therapeutics in the third quarter valued at about $47,000. Barclays PLC lifted its holdings in shares of Gyre Therapeutics by 281.8% during the 3rd quarter. Barclays PLC now owns 9,288 shares of the company’s stock valued at $116,000 after purchasing an additional 6,855 shares during the last quarter. State Street Corp grew its stake in shares of Gyre Therapeutics by 8.8% during the third quarter. State Street Corp now owns 104,490 shares of the company’s stock worth $1,310,000 after acquiring an additional 8,412 shares during the last quarter. Rhumbline Advisers purchased a new stake in Gyre Therapeutics during the 2nd quarter worth approximately $123,000. Finally, Renaissance Technologies LLC acquired a new position in shares of Gyre Therapeutics in the 2nd quarter valued at $166,000. 23.99% of the stock is owned by hedge funds and other institutional investors.

About Gyre Therapeutics

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.